Adult Brain Tumors: Clinical Applications of Magnetic Resonance Spectroscopy

Neuroimaging Clinics of North America

Volumn 23, Issue 3, 2013, Pages 527-555

  Brandão, Lara A ^a,b   Castillo, Mauricio ^c  

^a Radiologic Clinic Felippe Mattoso   (Brazil)

^b Clinic IRM   (Brazil)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adult brain tumors; Differential diagnosis; Proton magnetic resonance spectroscopy (H MRS); Therapeutic response; Tumor extension; Tumor grade; Tumor histology; Tumor progression

Indexed keywords

ALANINE; CHOLINE; CREATINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LACTIC ACID; LIPID; N ACETYLASPARTIC ACID;

ADULT; BRACHYTHERAPY; BRAIN ABSCESS; BRAIN BIOPSY; BRAIN BLOOD FLOW; BRAIN LYMPHOMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER GRADING; CANCER PROGNOSIS; CEREBROVASCULAR ACCIDENT; CONTRAST ENHANCEMENT; CORTICAL DYSPLASIA; DEMYELINATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; ENCEPHALITIS; EPENDYMOMA; GAMMA KNIFE RADIOSURGERY; GLIOBLASTOMA; GLIOMA; GLIOMATOSIS CEREBRI; HUMAN; MEDULLOBLASTOMA; MENINGIOMA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGODENDROGLIOMA; PERFUSION WEIGHTED IMAGING; PILOCYTIC ASTROCYTOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIATION NECROSIS; REVIEW; SURVIVAL PREDICTION; TUMOR CLASSIFICATION; TUMOR GROWTH; TUMOR NECROSIS; TUMOR RECURRENCE;

EID: 84881375929     PISSN: 10525149     EISSN: 15579867     Source Type: Journal    
DOI: 10.1016/j.nic.2013.03.002     Document Type: Review

References (158)

1. Bottomley P.A., Edelstein W.A., Foster T.H., et al. Invivo solvent suppressed localized hydrogen nuclear magnetic resonance spectroscopy: a window to metabolism?. Proc Natl Acad Sci U S A 1985, 82:2148-2152.
2. 1H NMR spectra of metabolites in the human brain. Proc Natl Acad Sci U S A 1988, 85:1821-1825.
3. Frahm J., Bruhn H., Gynell M.L., et al. Localized high resolution proton NMR spectroscopy using stimulated echoes: initial applications to human brain invivo. Magn Reson Med 1989, 9:79-93.
4. Bruhn H., Frahm J., Gynell M.L., et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy invivo: initial experience in patients with cerebral tumors. Radiology 1989, 172:541-548.
5. Bertholdo D, Watcharakorn A, Castillo M. Magnetic resonance spectroscopy: introduction and overview. Neuroimaging Clin North Am, in press.
6. Morita N., Harada M., Otsuka H., et al. Clinical application of MR spectroscopy and imaging of brain tumor. Magn Reson Med Sci 2010, 9(4):167-175.
7. Al-Okaili R.N., Krejza J., Wang S., et al. Advanced MR imaging techniques in the diagnosis of intraaxial brain tumors in adults. Radiographics 2006, 26:173-189.
8. Al-Okaili R.N., Krejza J., Woo J.H., et al. Intraaxial brain masses: MR-imaging-based diagnostic strategy-initial experience. Radiology 2007, 243:539-550.
9. Majós C., Julià-Sapé M., Alonso J., et al. Brain tumor classification by proton MR spectroscopy: comparison of diagnostic accuracy at short and long TE. AJNR Am J Neuroradiol 2004, 25:1696-1704.
10. Brown T.R., Kinkaid B.M., Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci U S A 1982, 79:3523-3526.
11. Horska A., Baker P.B. Imaging of brain tumors: MR spectroscopy and metabolic imaging. Neuroimaging Clin N Am 2010, 20:293-310.
12. Hourani R., Horska A., Albayram S., et al. Proton magnetic resonance spectroscopic imaging to differentiate between non neoplatic lesions and brain tumors in children. JMagn Reson Imaging 2006, 23:99-107.
13. Majós C., Aguilera C., Alonso J., et al. Proton MR spectroscopy improves discrimination between tumor and pseudotumoral lesion in solid brain masses. AJNR Am J Neuroradiol 2009, 30:544-551.
14. Tzika A.A., Vajapeyam S., Barnes P.D. Multivoxel proton MR spectroscopy and hemodynamic MR imaging of childhood brain tumors: preliminary observations. AJNR Am J Neuroradiol 1997, 18:203-218.
15. Butzen J., Prost R., Chetty V., et al. Discrimination between neoplastic and non neoplastic brain lesions by use of proton MR spectroscopy. The limits of accuracy with a logistic regression model. AJNR Am J Neuroradiol 2000, 21:1213-1219.
16. Voge T.J., Jassoy A., Söllner O., et al. The proton MR spectroscopy of intracranial tumors. The differential diagnostic aspects for gliomas, metastases and meningeomas. Rofo 1992, 157:371-377. [in German].
17. Kinoshita Y., Yokota A. Absolute concentrations of metabolites in human brain tumors using invitro proton magnetic resonance spectroscopy. NMR Biomed 1997, 10:2-12.
18. Castillo M. Proton MR spectroscopy of the brain. Neuroimaging Clin N Am 1998, 8(4):733-752.
19. Rand SD. MR spectroscopy: single voxel. Presented at the 39th Annual Meeting of the American Society of Neuroradiology. Boston, April, 2001.
20. Michaelis T., Merboldt K.D., Bruhn H., et al. Absolute concentrations of metabolites in the adult human brain invivo: quantification of localized proton MR spectra. Neuroradiology 1993, 187:219-227.
21. Herminghaus S, Pilatus U, Raab P, etal. Impact of invivo proton MR spectroscopy for the assessment of the proliferative activity in viable and partly necrotic brain tumor tissue. Presented at the 39th Annual Meeting of the American Society of Neuroradiology. Boston, April, 2001.
22. Palasis S. Utility of short TE MR spectroscopy in determination of histology, grade and behavior of pediatric brain tumors. Presented at the 39th Annual Meeting of the American Society of Neuroradiology. Boston, April, 2001.
23. Herholz K., Heindel W., Luyten P.R., et al. Invivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992, 31:319-327.
24. Castillo M., Smith J.K., Kwock L. Correlation of myo-inositol levels and grading of cerebral astrocytomas. AJNR Am J Neuroradiol 2000, 21:1645-1649.
25. Pilatus U, Reichel C, Raab P, etal. ERM detectable lipid signal in low- and high-grade glioma, recurrent gliomas, metastases, lymphomas and abscesses. Presented at the 39th Annual Meeting of the American Society of Neuroradiology. Boston, April, 2001.
26. 1H magnetic resonance spectroscopy. Magn Reson Med 2003, 49:223-232.
27. 1H MRS of high-grade astrocytomas: mobile lipid accumulation in necrotic tissue. NMR Biomed 1994, 7:149-155.
28. Di Costanzo A., Scarabino T., Trojsi F., et al. Proton MR spectroscopy of cerebral gliomas at 3 T: spatial heterogeneity, and tumour grade and extent. Eur Radiol 2008, 18:1727-1735.
29. Hawley J, Pennizi A, Paul C, etal. Clinical evaluation of ultrashort TE proton spectroscopy imaging of the brain. Presented at the 39th Annual Meeting of the American Society of Neuroradiology. Boston, April, 2001.
30. Fan G., Sun B., Wu Z., et al. Invivo single-voxel proton MR spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin Radiol 2004, 59:77-85.
31. Law M., Cha S., Knopp E.A., et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002, 222:715-721.
32. Chiang I.C., Kuo Y.T., Lu C.Y., et al. Distinction between high-grade gliomas and solitary metastases using peritumoral 3-T magnetic resonance spectroscopy, diffusion, and perfusion imagings. Neuroradiology 2004, 46:619-627.
33. Ricci R., Bacci A., Tugnoli V., et al. Metabolic findings on 3T H-MR spectroscopy in peritumoral brain edema. AJNR Am J Neuroradiol 2007, 28:1287-1291.
34. Burtscher I.M., Skagerberg G., Geijer B., et al. Proton MR spectroscopy and preoperative diagnostic accuracy: an evaluation of intracranial mass lesions characterized by stereotactic biopsy findings. AJNR Am J Neuroradiol 2000, 21:84-93.
35. Weber M.A., Zoubaa S., Schlieter M., et al. Diagnostic performance of spectroscopic and perfusion MR for distinction of brain tumors. Neurology 2006, 66:1899-1906.
36. Demir M.K., Iplikcioglu A.C., Dincer A., et al. Single voxel proton MR spectroscopy findings of typical and atypical intracranial meningiomas. Eur J Radiol 2006, 60:48-55.
37. Bulakbasi N., Kocaoglu M., Örs F., et al. Combination of single-voxel proton MR spectroscopy and apparent diffusion coefficient calculation in the evaluation of common brain tumors. AJNR Am J Neuroradiol 2003, 24:225-233.
38. Rabin B.M., Meyer J.R., Berlin J.W., et al. Radiation-induced changes in the central nervous system and head and neck. Radiographics 1996, 16:1055-1072.
39. Kado H., Ogawa T., Hatazawa J., et al. Radiation-induced meningioma evaluated with positron emission tomography with fludeoxyglucose F 18. AJNR Am J Neuroradiol 1996, 17:937-938.
40. Zacharia T.T., Law M., Naidich T.P., et al. Central nervous system lymphoma characterization by diffusion-weighted imaging and MR spectroscopy. JNeuroimaging 2008, 18:411-417.
41. Hakyemez B., Erdogan C., Bolca N., et al. Evaluation of different cerebral mass lesions by perfusion-weighted MR imaging. JMagn Reson Imaging 2006, 24:817-824.
42. Law M., Yang S., Wang H., et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MRimaging. AJNR Am J Neuroradiol 2003, 24:1989-1998.
43. Brandão L., Domingues R. Intracranial neoplasms. MR spectroscopy of the brain 2002, 130-167. Lippincott Williams & Wilkins, Philadelphia. L. McAllister, T. Lazar, R.E. Cook (Eds.).
44. Knopp EA. Advanced MR imaging of tumors: using spectroscopy and perfusion. Presented at the 39th Annual Meeting of the American Society of Neuroradiology. Boston, April, 2001.
45. Taillibert S., Chodkiewicz C., Laigle-Donadey F., et al. Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature. JNeurooncol 2006, 76:201-205.
46. Mohana-Borges A.V., Imbesi S.G., Dietrich R., et al. Role of proton magnetic resonance spectroscopy in the diagnosis of gliomatosis cerebri. JComput Assist Tomogr 2004, 28(1):103-105.
47. Sarafi-Lavi E., Bowen B.C., Pattany P.M., et al. Proton MR spectroscopy of gliomatosis cerebri: case report of elevated myoinositol with normal choline levels. AJNR Am J Neuroradiol 2003, 24:946-951.
48. 1H MR spectroscopy in the assessment of gliomatosis cerebri. AJR Am J Roentgenol 2007, 188:710-714.
49. Galanaud D., Chinot O., Nicoli F., et al. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. JNeurosurg 2003, 98:269-276.
50. Tong Z., Yamaki T., Harada K., et al. Invivo quantification of the metabolites in normal brain and brain tumors by proton MR spectroscopy using water as an internal standard. Magn Reson Imaging 2004, 22:1017-1024.
51. 1H-MR spectroscopy of untreated pediatric brain tumors: preoperative diagnosis and characterization. AJNR Am J Neuroradiol 2006, 27:560-572.
52. 1H-MR spectroscopy. JMagn Reson Imaging 2007, 26:1390-1398.
53. Majós C., Aguilera C., Cós M., et al. Invivo proton magnetic resonance spectroscopy of intraventricular tumors of the brain. Eur Radiol 2009, 19:2049-2059.
54. 1H magnetic resonance spectroscopy and diffusion-perfusion magnetic resonance imaging for preoperative diagnosis: case report. Neurosurgery 2006, 58(4):E789.
55. Yamasaki F., Kurisu K., Satoh K., et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 2005, 235:985-991.
56. 1H NMR spectroscopy studies of extracts of human cerebral neoplasms. Magn Reson Med 1992, 24:123-126.
57. Raybaud C., Barkovich A.J. Intracranial, orbital and neck masses of childhood. Pediatric neuroimaging 2012, 637-711. Lippincott Williams & Wilkins, Philadelphia. 5th edition. A.J. Barkovich, C. Raybaud (Eds.).
58. Barkovich A. Intracranial, orbital and neck masses of childhood. Pediatric neuroimaging 2005, 637-750. Lippincott Williams & Wilkins, Philadelphia. 5th edition. A.J. Barkovich, C. Raybaud (Eds.).
59. Blaser S.I., Harwood-Nash D.C. Neuroradiology ofpediatric posterior fossa medulloblastoma. JNeurooncol 1996, 29:23-34.
60. Kleihues P., Cavenee W.K. World Health Organization classification of tumors: pathology and genetics of tumors of the central nervous system 2000, IARC Press, Lyon (France).
61. Yuh E.L., Barkovich A.J., Gupta N. Imaging of ependymomas: MRI and CT. Childs Nerv Syst 2009, 25:1203-1213.
62. Uematsu Y., Hirano A., Llena J.F. Electron microscopic observations of blood vessels in ependymoma. No Shinkei Geka 1988, 16:1235-1242. [in Japanese].
63. 1H MRS for childhood cerebellar tumors prior to histopathological diagnosis. Pediatr Radiol 2007, 37:1101-1109.
64. Bourgouin P.M., Tampieri D., Grahovac S.Z., et al. CT and MR imaging findings in adults with cerebellar medulloblastoma: comparison with findings in children. AJR Am J Roentgenol 1992, 159:609-612.
65. Movsas B., Li B.S., Babb J.S. Quantifying radiation therapy-induced brain injury with whole-brain proton MR spectroscopy: initial observations. Radiology 2001, 221:327-331.
66. Ricci P.E., Pitt A., Keller P.J., et al. Effect of voxel position on single-voxel MR spectroscopy findings. AJNR Am J Neuroradiol 2000, 21:367-374.
67. Chawla S., Wang S., Wolf R.L., et al. Arterial spin labeling and MR spectroscopy in the differentiation of gliomas. AJNR Am J Neuroradiol 2007, 28:1683-1689.
68. Hollingworth W., Medina L.S., Lenkinski R.E., et al. Asystematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors. AJNR Am J Neuroradiol 2006, 27:1404-1411.
69. Di Costanzo A., Scarabino T., Trojsi F., et al. Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy. Neuroradiology 2006, 48:622-631.
70. Chang S.M., Nelson S., Vandenberg S., et al. Integration of preoperative anatomic and metabolic physiologic imaging of newly diagnosed glioma. JNeurooncol 2009, 92:401-415.
71. Arnold D.L., Shoubridge E.A., Villemure J.G., et al. Proton and phosphorus magnetic resonance spectroscopy of human astrocytomas invivo. Preliminary observations on tumor grading. NMR Biomed 1990, 3:184-189.
72. Gill S.S., Thomas D.G., Van Bruggen N., et al. Proton MR spectroscopy of intracranial tumours: invivo and invitro studies. JComput Assist Tomogr 1990, 14:497-504.
73. Preul M.C., Leblanc R., Caramanos Z., et al. Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases. Can J Neurol Sci 1998, 25:13-22.
74. Majós C., Bruna J., Julià-Sapé M., et al. Proton MR spectroscopy provides relevant prognostic information in high-grade astrocytomas. AJNR Am J Neuroradiol 2011, 32:74-80.
75. Rock J.P., Hearshen D., Scarpace L., et al. Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis. Neurosurgery 2002, 51:912-919.
76. Covarrubias D.J., Rosen B.R., Lev M.H. Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004, 9:528-537.
77. Isobe T., Matsumura A., Anno I., et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002, 20:343-349.
78. 23Na MR imaging. AJNR Am J Neuroradiol 2008, 29:464-470.
79. 1H MR spectroscopic imaging. NMR Biomed 2003, 16:12-18.
80. Gupta R.K., Cloughesy T.F., Sinha U., et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. JNeurooncol 2000, 50:215-226.
81. Ishimaru H., Morikawa M., Iwanaga S., et al. Differentiation between high-grade glioma and metastatic brain tumor using single-voxel proton MR spectroscopy. Eur Radiol 2001, 11:1784-1791.
82. 1H MR spectroscopy-initial results. Radiology 1999, 213:785-793.
83. WHO classification of tumours of the central nervous system 2007, IARC, Lyon (France), 978-92-832-2430-2. D.N. Louis, H. Ohgaki, O.D. Wiestler (Eds.).
84. Lev M.H., Ozsunar Y., Henson J.W., et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004, 25:214-221.
85. Cha S., Tihan T., Crawford F., et al. Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol 2005, 26:266-273.
86. Spampinato M.V., Smith J.K., Kwock L., et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol 2007, 188:204-212.
87. Xu M., See S.J., Ng W.H., et al. Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery 2005, 56:919-926.
88. Pirzkall A., McKnight T.R., Graves E.E., et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001, 50:915-928.
89. Ganslandt O., Stadlbauer A., Fahlbusch R., et al. Proton magnetic resonance spectroscopic imaging integrated into image-guided surgery: correlation to standard magnetic resonance imaging and tumor cell density. Neurosurgery 2005, 56:291-298.
90. McKnight T.R., Von Dem Bussche M.H., Vigneron D.B., et al. Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. JNeurosurg 2002, 97:794-802.
91. Poussaint T.Y. Pediatric brain tumors. Handbook of neuro-oncology neuroimaging 2008, 469-484. Academic Press, New York. H.B. Newton, F.A. Jolesz (Eds.).
92. Croteau D., Scarpace L., Hearshen D., et al. Correlation between magnetic resonance spectroscopy imaging and image-guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery 2001, 49:823-829.
93. Stadlbauer A., Nimsky C., Buslei R., et al. Proton magnetic resonance spectroscopic imaging in the border zone of gliomas: correlation of metabolic and histological changes at low tumor infiltration-initial results. Invest Radiol 2007, 42:218-223.
94. Kallenberg K., Bock H.C., Helms G. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 2009, 253(3):805-812.
95. Luyten P.R., Marien A.J., Heindel W., et al. Metabolic imaging of patients with intracranial tumors: H-1 MR spectroscopic imaging and PET. Radiology 1990, 176:791-799.
96. 1H magnetic resonance spectroscopy. Surg Neurol 1995, 44:137-144.
97. Nelson S.J., Huhn S., Vigneron D.B., et al. Volume MRI and MRSI techniques for the quantitation of treatment response in brain tumors: presentation of a detailed case study. JMagn Reson Imaging 1997, 7:1146-1152.
98. Kelly P.J., Daumas-Duport C., Scheithauer B.W., et al. Stereotactic histologic correlations of computed tomography- and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 1987, 62:450-459.
99. Martin A.J., Liu H., Hall W.A., et al. Preliminary assessment of turbo spectroscopic imaging for targeting in brain biopsy. AJNR Am J Neuroradiol 2001, 22:959-968.
100. Klingebiel R., Bohner G. Neuroimaging. Recent Results Cancer Res 2009, 171:175-190.
101. Dowling C., Bollen A.W., Noworolski S.M., et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 2001, 22:604-612.
102. Hall W.A., Martin A., Liu H., et al. Improving diagnostic yield in brain biopsy: coupling spectroscopic targeting with real-time needle placement. JMagn Reson Imaging 2001, 13:12-15.
103. Hall W.A., Galicich W., Bergman T., et al. 3-Tesla intraoperative MR imaging for neurosurgery. JNeurooncol 2006, 77:297-303.
104. 1H-chemical-shift imaging of choline. Stereotact Funct Neurosurg 2008, 86:300-307.
105. Tedeschi G., Lundbom N., Ramon R., et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. JNeurosurg 1997, 87:516-524.
106. Castillo M., Kwock L. Proton MR spectroscopy of common brain tumors. Neuroimaging Clin N Am 1998, 8:733-752.
107. Oh J., Henry R.G., Pirzkall A., et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. JMagn Reson Imaging 2004, 19:546-554.
108. Kuznetsov Y.E., Caramanos Z., Antel S.B., et al. Proton magnetic resonance spectroscopic imaging can predict length of survival in patients with supratentorial gliomas. Neurosurgery 2003, 53:565-574. [discussion: 574-76].
109. 1H MRSI parameters that may predict survival for patients with malignant gliomas. NMR Biomed 2004, 17:10-20.
110. Saraswathy S., Crawford F.W., Lamborn K.R., et al. Evaluation of MR markers that predict survival in patients with newly diagnosed GBM prior to adjuvant therapy. JNeurooncol 2009, 91:69-81.
111. Crawford F.W., Khayal I.S., McGue C., et al. Relationship of pre-surgery metabolic and physiological MR imaging parameters to survival for patients with untreated GBM. JNeurooncol 2009, 91:337-351.
112. Arslanoglu A., Bonekamp D., Barker P.B., et al. Quantitative proton MR spectroscopic imaging of the mesial temporal lobe. JMagn Reson Imaging 2004, 20:772-778.
113. Chan A.A., Lau A., Pirzkall A., et al. Proton magnetic resonance spectroscopy imaging in the evaluation of patients undergoing gamma knife surgery for Grade IV glioma. JNeurosurg 2004, 101:467-475.
114. Raizer J.J., Koutcher J.A., Abrey L.E., et al. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma. JNeurooncol 2005, 71:173-180.
115. Hattingen E., Raab P., Franz K., et al. Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 2008, 50:759-767.
116. Yang I., Aghi M.K. New advances that enable identification of glioblastoma recurrence. Nat Rev Clin Oncol 2009, 6:648-657.
117. Rabinov J.D., Lee P.L., Barker F.G., et al. Invivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002, 225:871-879.
118. Smith E.A., Carlos R.C., Junck L.R., et al. Developing aclinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiationchange in patients with new contrast-enhancing lesions. AJR Am J Roentgenol 2009, 192:W45-W52.
119. Weybright P., Sundgren P.C., Maly P., et al. Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy. AJR Am J Roentgenol 2005, 185:1471-1476.
120. Zeng Q.S., Li C.F., Liu H., et al. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 2007, 68:151-158.
121. Cha S. Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006, 27:475-487.
122. Weber M.A., Giesel F.L., Stieltjes B. MRI for identification of progression in brain tumors: from morphology to function. Expert Rev Neurother 2008, 8:1507-1525.
123. Sundgren P.C. MR spectroscopy in radiation injury. AJNR Am J Neuroradiol 2009, 30:1469-1476.
124. 1H MRSI. JMagn Reson Imaging 2002, 16:464-476.
125. Taylor J.S., Langston J.W., Reddick W.E., et al. Clinical value of proton magnetic resonance spectroscopy for differentiating recurrent or residual brain tumor from delayed cerebral necrosis. Int J Radiat Oncol Biol Phys 1996, 36:1251-1261.
126. Graves E.E., Nelson S.J., Vigneron D.B., et al. Serialproton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 2001, 22:613-624.
127. 1H MR spectroscopic imaging for increasing diagnostic accuracy. Neuroradiology 2005, 47:826-834.
128. Wald L.L., Nelson S.J., Day M.R., et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. JNeurosurg 1997, 87:525-534.
129. Chernov M.F., Hayashi M., Izawa M., et al. Multivoxel proton MRS for differentiation of radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases. Brain Tumor Pathol 2006, 23:19-27.
130. Law M. MR spectroscopy of brain tumors. Top Magn Reson Imaging 2004, 15:291-313.
131. Li X., Vigneron D.B., Cha S., et al. Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas invivo. AJNR Am J Neuroradiol 2005, 26:760-769.
132. Elias A.E., Carlos R.C., Smith E.A., et al. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury. Acad Radiol 2011, 18:1101-1108.
133. Murphy P.S., Viviers L., Abson C., et al. Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy. Br J Cancer 2004, 90:781-786.
134. Lewin JS. Percutaneous MR image-guided procedures in neuroradiology. Presented at the 39th Annual Meeting of the American Society of Neuroradiology. Boston, April, 2001.
135. Hourani R., Brant L.S., Rizk T., et al. Can proton MR spectroscopic and Perfusion Imaging Differentiate Between Neoplastic and Nonneoplastic Brain Lesions in Adults?. AJNR Am J Neuroradiol 2008, 29:366-372.
136. Sundgren P.C., Nagesh V., Elias A., et al. Metabolic alterations: a biomarker for radiation-induced normal brain injury-an MR spectroscopy study. JMagn Reson Imaging 2009, 29:291-297.
137. Esteve F., Rubin C., Grand S., et al. Transient metabolic changes observed with proton MR spectroscopy in normal human brain after radiation therapy. Int J Radiat Oncol Biol Phys 1998, 40:279-286.
138. Rand S.D., Prost R., Haughton V., et al. Accuracy of single-voxel proton MR spectroscopy in distinguishing neoplastic from non neoplastic brain lesions. AJNR Am J Neuroradiol 1997, 18:1695-1704.
139. Paley R.J., Persing J.A., Doctor A., et al. Multiple sclerosis and brain tumor: a diagnostic challenge. JEmerg Med 1989, 7:241-244.
140. Giang D.W., Poduri K.R., Eskin T.A., et al. Multiple sclerosis masquerading as a mass lesion. Neuroradiology 1992, 34:150-154.
141. Hunter S.B., Ballinger W.E., Rubin J.J. Multiple sclerosis mimicking primary brain tumor. Arch Pathol Lab Med 1987, 111:464-468.
142. Kurihara N., Takahashi S., Furuta A., et al. MR imaging of multiple sclerosis simulating brain tumor. Clin Imaging 1996, 20:171-177.
143. Mastrostefano R., Occhipinti E., Bigotti G., et al. Multiple sclerosis plaque simulating cerebral tumor: case report and review of the literature. Neurosurgery 1987, 21:244-246.
144. Silva H.C., Callegaro D., Marchiori P.E., et al. Magnetic resonance imaging in five patients with a tumefactive demyelinating lesion in the central nervous system. Arq Neuropsiquiatr 1999, 57:921-926.
145. Tate A.R., Underwood J., Acosta D., et al. Development of a decision support system for diagnosis and grading of brain tumours using invivo magnetic resonance single voxel spectra. NMR Biomed 2006, 19:411-434.
146. Preul M.C., Caramanos Z., Collins D.L., et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996, 2:323-325.
147. 1H MRS) of human brain tumors: assessment of differences between tumour types and its applicability in brain tumour categorization. Eur Radiol 2003, 13:582-591.
148. 1H magnetic resonance spectroscopic imaging. Ann Neurol 1998, 44:273-278.
149. Saindane A.M., Cha S., Law M., et al. Proton MR spectroscopy of tumefactive demyelinating lesions. AJNR Am J Neuroradiol 2002, 23:1378-1386.
150. Cianfoni A., Niku S., Imbesi S.G., et al. Metabolite findings in tumefactive demyelinating lesions utilizing short echo time proton magnetic resonance spectroscopy. AJNR Am J Neuroradiol 2007, 28:272-277.
151. Srinivasan R., Sailasuta N., Hurd R., et al. Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T. Brain 2005, 128:1016-1025.
152. Bitsch A., Bruhn H., Vougioukas V., et al. Inflammatory CNS demyelination: histopathologic correlation with invivo quantitative proton MR spectroscopy. AJNR Am J Neuroradiol 1999, 20:1619-1627.
153. Fernando K.T., McLean M.A., Chard D.T., et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004, 127:1361-1369.
154. Vuori K., Kankaanranta L., Häkkinen A.M., et al. Low-grade gliomas and focal cortical developmental malformations: differentiation with proton MR spectroscopy. Radiology 2004, 230(3):703-708.
155. Pal D., Bhattacharyya A., Husain M., et al. Invivo proton MR spectroscopy evaluation of pyogenic brain abscesses: a report of 194 cases. AJNR Am J Neuroradiol 2010, 31:360-366.
156. Lai P.H., Ho J.T., Chen W.L., et al. Brain abscess and necrotic brain tumor: discrimination with proton MR spectroscopy and diffusion-weighted imaging. AJNR Am J Neuroradiol 2002, 23(8):1369-1377.
157. Samann P.G., Schlegel J., Muller G., et al. Serial proton MR spectroscopy and diffusion imaging findings in HIV-related herpes simplex encephalitis. AJNR Am J Neuroradiol 2003, 24:2015-2019.
158. Law M., Hamburger M., Johnson G., et al. Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging. Technol Cancer Res Treat 2004, 3:557-565.